目的：分析伏立康唑治疗真菌性肺炎的临床价值。方法收集我院2011年8月~2013年8月诊治的真菌性肺炎患者60例作为研究对象，以抛硬币的方式分为试验组与对照组，每组患者各30例。对照组患者采用常规氟康唑治疗，试验组采用伏立康唑治疗，对两组患者的治疗效果进行分析对比。结果研究结果显示，经2个疗程的治疗之后，试验组中真菌清除24例，另外6例患者在2个疗程之后真菌仍未清除，真菌清除率为80.0%。对照组中真菌清除17例，另外13例患者在两个疗程之后真菌仍未清除，真菌清除率为56.67%。试验组真菌清除率明显高于对照组(<0.05)。试验组中有19例(63.33%)显效，8例(26.67%)有效，3例(10.0%)无效，总有效率为90.0%；对照组中有14例(46.67%)显效，8例(26.67%)有效，8例(26.67%)无效，总有效率为73.33%，试验组患者的治疗效果明显优于对照组(<0.05)。结论伏立康唑治疗真菌性肺炎能有效提高真菌清除率和整体治疗效果，具有良好的临床价值，值得在临床应用上推广。%Objective To analyze the clinical value of voriconazole in the treatment of fungal pneumonia.Methods In our hospital during 2011~2013 in diagnosis and treatment of patients with fungal pneumonia in 60 cases as theresearch object,randomly divided into two groups,comparing two groups ofpatients.Results The results showed that,much bet er than the treatment ef ect of test group patients were compared with a control group( <0.05).Conclusion Fushita Yasu in the treatment of fungal pneumonia can ef ectively improve the fungal clearance rate and the overal treatment ef ect,has good clinical value, worthy of promotion in clinical application.
展开▼
